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Metastasis-associated in colon cancer 1 (MACC1) and S100 calcium-bind-
ing protein A4 (S100A4) are prominent inducers of tumor progression and
metastasis. For the first time, we systematically tracked circulating serum
levels of MACC1 and S100A4 transcripts in the course of surgery and
chemotherapy and analyzed their clinical relevance for ovarian cancer.
MACC1 and S100A4 transcripts were quantified in a total of 318 serum
samples from 79 ovarian cancer patients by RT-qPCR and digital droplet
PCR, respectively. MACC1 and S100A4 transcripts were significantly ele-
vated in serum of ovarian cancer patients, compared to healthy controls
(P = 0.024; P < 0.001). At primary diagnosis, high levels of MACC1 or
S100A4 correlated with advanced FIGO stage (P = 0.042; P = 0.008), pre-
dicted suboptimal debulking surgery and indicated shorter progression-free
survival (PFS; P = 0.003; P = 0.001) and overall survival (OS; P = 0.001;
P = 0.002). This is the first study in ovarian cancer to propose circulating
MACC1 and S100A4 transcripts as potential liquid biopsy markers.
Abbreviations
ASA, American Society of Anesthesiologists; AUC, area under the curve; BRCA1, breast cancer 1, early onset; CA125, cancer-antigen 125;
CI, confidence interval; CRC, colorectal cancer; ddPCR, droplet digital polymerase chain reaction; ED, estimated difference; EMT, epithelial-
to-mesenchymal transition; FIGO, Federation Internationale de Gynecologie et d’Obstetrique; HGF, hepatocyte growth factor; HR, hazard
ratio; MACC1, Metastasis-associated in colon cancer 1; MET, MET proto-oncogene, receptor tyrosine kinase; OS, overall survival; PARP,
poly(ADP-ribose) polymerase; PFS, progression-free survival; ROC, receiver operating characteristic; RT-qPCR, real-time quantitative
polymerase chain reaction; S1004A, S100 calcium-binding protein A4.
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1. Introduction
Ovarian cancer is the leading cause of death among
female malignancies. At primary diagnosis, approxi-
mately 70% of all ovarian cancer patients already pre-
sent with advanced tumor stages (Goodman et al.,
2003). Standard treatment of advanced ovarian cancer
is primary radical surgery aiming at macroscopic com-
plete tumor resection followed by platinum- and pacli-
taxel-based chemotherapy, which prolongs progression-
free survival (PFS) and overall survival (OS) (du Bois
et al., 2005; Karam et al., 2017). Postoperative residual
tumor load is one of the most important prognostic fac-
tors in advanced ovarian cancer (Wimberger et al.,
2010). Despite improved primary radical surgery and
the implementation of innovative targeted therapies into
standard treatment of ovarian cancer, such as anti-
angiogenetic therapy with bevacizumab or PARP inhi-
bitors, ovarian cancer patients still have a poor overall
prognosis (Burger et al., 2011; Ledermann et al., 2014).
Considering this clinical challenge, it would be highly
desirable to establish additional blood-based biomark-
ers, which can predict recurrence risk and prognosis.
In previous studies, we focused on two human
metastasis-inducing genes: metastasis-associated in
colon cancer 1 (MACC1) and S100 calcium-binding
protein A4 (S100A4). MACC1 was newly identified
and named by our group (Stein et al., 2009a). MACC1
is a key regulator of HGF-MET signaling and a deci-
sive driver of metastasis in human colorectal cancer
(CRC) (Arlt and Stein, 2009; Stein et al., 2009a,b).
MACC1 promotes metastasis as a regulator of further
metastasis-associated genes by acting as a transcription
factor and/or via protein–protein interactions.
MACC1 induces fundamental processes like prolifera-
tion, migration, and invasiveness resulting in tumor
progression and metastasis in xenografted and trans-
genic mouse models (Lemos et al., 2016; Mudduluru
et al., 2017; Stein et al., 2010). We and others reported
that MACC1 levels in early primary CRC predict
metastasis formation and poor survival (Ilm et al.,
2015; Koelzer et al., 2015; Nitsche et al., 2012; Stein
et al., 2009a). These findings have been confirmed by
more than 190 successive publications for more than
20 other human solid malignancies.
S100A4 belongs to the family of S100 proteins,
which are a highly similar group of small Ca2+-bind-
ing proteins with a molecular mass of 10–12 kDa
(Dahlmann et al., 2016; Zimmer et al., 2013). S100
proteins are involved in numerous different cellular
functions, such as proliferation, differentiation, or
apoptosis (Donato et al., 2013). Enhanced cell growth
and motility, associated with elevated S100A4 expres-
sion, was shown to increase the metastatic potential of
cancer cells among a variety of malignancies, such as
breast cancer, lung cancer, or CRC (Bresnick et al.,
2015). S100A4 was identified as transcriptional target
of the Wnt/b-catenin signaling pathway. Targeting this
pathway decreased S100A4 expression and reduced
metastasis formation in a CRC mouse model (Sack
et al., 2011; Stein et al., 2006).
Transferring this to a liquid biopsy approach, we
have recently established a sensitive blood-based assay
for detecting the transcripts of MACC1 and S100A4
in serum/plasma. We showed that (a) MACC1 mRNA
transcripts are detectable in plasma of patients with
CRC or gastric cancer, (b) they are significantly ele-
vated compared to healthy controls, and that (c) high
levels of circulating MACC1 transcripts indicate poor
survival (Ashktorab et al., 2016; Burock et al., 2015;
Lederer et al., 2015; Rohr et al., 2017; Stein et al.,
2012). Furthermore, we have confirmed the diagnostic
and prognostic value of S100A4 transcripts in plasma
of patients with CRC or gastric cancer, particularly by
combined assessment, together with MACC1 tran-
scripts (Burock et al., 2015; Stein et al., 2011, 2012).
Oncogenic function of MACC1 and S100A4 has
likewise been proposed for ovarian cancer. It was
reported that both genes are overexpressed in ovarian
cancer and this overexpression was associated with
increased migration, chemoresistance, and epithelial-
to-mesenchymal transition (EMT) (Kikuchi et al.,
2006; Li et al., 2015; Yan et al., 2016; Yu et al., 2017;
Zhang et al., 2016). However, clinical relevance of
MACC1 and S100A4 transcripts as potential blood-
based biomarkers for ovarian cancer patients is
1269Molecular Oncology 13 (2019) 1268–1279 ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
T. Link et al. Circulating MACC1 and S100A4 in ovarian cancer
completely unknown. Therefore, we inquired (a)
whether we can detect MACC1 and S100A4 mRNA
transcripts in serum of ovarian cancer patients at a
level that significantly differs from healthy controls
and (b) whether MACC1 and S100A4 transcript levels
at primary diagnosis and in the course of surgery and
adjuvant chemotherapy could have the potential as liq-
uid biopsy markers for ovarian cancer.
2. Materials and methods
2.1. Patient characteristics
The study methodologies conformed to the standards
set by the Declaration of Helsinki. Our study was con-
ducted at the Department of Gynecology and Obstet-
rics at the Carl Gustav Carus University of Dresden,
TU Dresden, Germany. In this study, a total of 79
patients with histologically confirmed primary epithe-
lial ovarian cancer were enrolled. Informed written
consent was obtained from all patients, and the study
was approved by the Local Research Ethics Commit-
tee in Dresden (EK74032013). The patients’ clinical
data are summarized in Table 1. Tumors were classi-
fied according to the WHO classification of tumors of
the female genital tract. Grading was conducted using
the grading system proposed by Silverberg (Silverberg,
2000), and tumor staging was classified according to
the Federation Internationale de Gynecologie et
d’Obstetrique (FIGO) (FIGO Committee on Gyneco-
logic Oncology 2009). The whole study population
received primary radical surgery aiming at macro-
scopic complete tumor resection followed by platinum-
and paclitaxel-based adjuvant chemotherapy. Beva-
cizumab, which is approved for patients with a tumor
stage of at least FIGO IIIb, was additionally adminis-
tered to 66% of all patients.
2.2. Serum preparation and RNA isolation
Following blood withdrawal with a 7.5-mL S-Monov-
ette (Sarstedt AG & Co., Nuembrecht, Germany),
obtained blood samples were incubated at room temper-
ature for at least 30 min to allow complete blood coagu-
lation. Within 1 h post-blood drawing, serum was
prepared by centrifugation for 8 min at 1800 g at room
temperature. The obtained cell-free serum fraction was
immediately frozen at 80 °C until further processing.
Unnecessary freeze–thaw cycles were avoided. Samples
were blinded so that neither time of blood drawing nor
any other information was disclosed during analysis.
Samples were thawed on ice and immediately processed
after complete thawing. For isolation of total RNA, the
High Pure Viral RNA Kit (Roche Diagnostics, Man-
nheim, Germany) was used according to the manufac-
turer’s instruction as described previously (Ashktorab
et al., 2016; Burock et al., 2015; Stein et al., 2011,
2012). Briefly, 350 lL serum was mixed with binding
buffer, supplemented with Poly(A) carrier RNA
(50 lgmL1). After RNA binding to the columns and
washing steps, RNA was eluted in nuclease-free water.
2.3. Real-time quantitative polymerase chain
reaction
For reverse transcription 1xPCR buffer II (Life Tech-
nologies, Carlsbad, CA, USA), 5 mM MgCl2 (Life Tech-
nologies), 1 mM of each dNTP (Roboklon, Berlin,
Germany), 2.5 lM random hexamers (Life Technolo-
gies), 1 UlL1 RNase inhibitor (Applied Biosystems,
Foster City, CA, USA), and 2.5 UlL1 MuLV reverse
transcriptase (Applied Biosystems) were used to tran-
scribe isolated serum RNA. Reaction was performed in
a PCR cycler at 23 °C for 15 min, 42 °C for 45 min,
and 95 °C for 5 min in a volume of 20 lL. MACC1
transcript levels were quantified using a Roche LightCy-
cler 480 (Roche) and GoTaq Probe qPCR Master Mix
(Promega Corporation, Madison, WI, USA) following
manufacturer’s instructions. Briefly, 1x master mix sup-
plemented with 0.5 lM of each primer (fw: TTC TTT
Table 1. Patient characteristics.
Total number of patients 79
Age Median 60 years, (21–82 years)
FIGO stage
I-II 16 (20%)
III-IV 63 (80%)
Grading
I 3 (4%)
II–III 76 (96%)
Residual tumor
Macroscopic complete
resection
36 (46%)
Any residual tumor 43 (54%)
Histologic type
Serous 63 (80%)
Others 16 (20%)
Recurrence
PFS Median 556 days (33–
1637 days)
No relapse 38 (48%)
Relapse 41 (52%)
Survival
OS Median 655 days (33–
1637 days)
Alive 57 (72%)
Dead 22 (28%)
OS, overall survival; PFS, progression-free survival.
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TgA TTC CTC Cgg TgA, rev: ACT CTg ATg ggC ATg
TgC Tg) and 0.3 lM probes (gCA gAC TTC CTC AAg
AAA TTC Tgg AAg ATC TA –FL, LC640-AgT gTT
TCA gAA CTT CTg gAC ATT TTA gAC gA-P; syn-
theses of primers and probes: BioTeZ and TIB MolBiol,
Berlin, Germany) and water were mixed in duplicate
with 2 lL cDNA to a final volume of 10 lL. PCR was
performed at 95 °C for 2 min followed by 40x 95 °C for
3 s, 60 °C for 5 s, and 60 °C for 25 s with data acquisi-
tion after the primer annealing step at the first 60 °C
incubation step and a melting curve from 40 °C to
95 °C. MACC1 mRNA expressions are given as per-
centage of the mRNA expression of a calibrator sample,
which was set 100%. Quantification was performed
using serial dilutions of a calibrator sample. The calibra-
tor cDNA derived from the cell line SW620 [authentica-
tion of the cell line by short tandem repeat (STR)
genotyping, German Collection of Microorganisms and
Cell Cultures, Braunschweig, Germany]. Each sample
was run and calculated in duplicate, and mean values
are indicated. Data analysis was performed using the
LIGHTCYCLER software.
2.4. Droplet digital polymerase chain reaction
S100A4 transcript levels were quantified using a Bio-
Rad QX200 Droplet Digital PCR System (Bio-Rad
Laboratories GmbH, Munich, Germany) and droplet
digital polymerase chain reaction (ddPCR) Supermix
for Probes (Bio-Rad) following manufacturer’s instruc-
tions. Briefly, 1x master mix supplemented with primer
probe mix (qHsaCEP0055305, Bio-Rad) and cDNA.
Droplet generation for ddPCR was done following
manufacturer’s instructions using the QX200 droplet
generator. Briefly, 20 lL PCR mix and 70 lL droplet
generator oil are given in the respective cavities of the
droplet generator cartridges (Bio-Rad). After droplet
generation, 40 lL droplet suspension was pipetted into
twin.tec 96-well PCR plates (Eppendorf, Hamburg,
Germany). PCR was performed at 95 °C for 10 min
followed by 39x 95 °C for 30 s and 60 °C for 60 s and
98 °C for 10 min using a T100 thermal cycler. Droplet
quantification was performed in the QX200 droplet
reader. The system counts all generated droplets and
detects the amount of PCR product-positive (fluores-
cent) droplets. Poisson correction of generated droplet
amount and data analysis was done using the QUANTA
LIFE (Bio-Rad) software.
2.5. Statistical analysis
Statistical analysis was performed using PYTHON Ver-
sion 3.6.4 (Python Software Foundation, Delaware,
USA) and GRAPHPAD PRISM version 7 for Windows
(GraphPad Software, La Jolla, CA, USA) and R-3.4.4
(Free Software Foundation’s GNU General Public
License). For this data analysis, P-values < 0.05 were
considered to be statistically significant. Evaluation of
circulating MACC1 and S100A4 was performed using
a nonparametric two-sided Mann–Whitney-U-Test. To
analyze, if MACC1 and S100A4 can discriminate
between ovarian cancer patients and healthy controls,
receiver operating characteristic (ROC) curve analysis
was performed. For estimating the correlation between
MACC1, S100A4, and CA125, Spearman’s rank corre-
lation test was performed. The change of MACC1 and
S100A4 transcripts levels during treatment was ana-
lyzed with the two-sided Wilcoxon rank-sum test for
paired data. Associations of MACC1 and S100A4 with
clinicopathological parameters were analyzed by the
nonparametric two-sided Mann–Whitney-U-Test. To
evaluate prognostic relevance of MACC1 and S100A4
transcript levels, univariate Cox regression was used
(with or without time dependency). A multivariate
Cox regression including established risk factors for
ovarian cancer (age, FIGO stage, residual tumor, his-
tology, state of health and amount of ascites) was
additionally performed. All models were tested for
both PFS und OS. In addition, Kaplan–Meier analysis
and the log-rank test were performed.
3. Results
3.1. Serum levels of MACC1 and S100A4
transcripts in ovarian cancer patients and their
dynamics in the course of surgery and adjuvant
chemotherapy
We analyzed the levels of serum MACC1 and S100A4
transcripts in a cohort of clinically documented ovar-
ian cancer patients at primary diagnosis (n = 77) and
compared it to the levels in serum of healthy controls
(n = 25). Moreover, we tracked the levels of both tran-
scripts in the course of primary surgery and adjuvant
chemotherapy, represented by four additional longitu-
dinal follow-up samples, obtained (a) one week after
primary surgery (n = 72), (b) before platinum-based
chemotherapy (n = 63), (c) after the third cycle of
chemotherapy (n = 53), and (d) after completion of
chemotherapy (n = 53).
Compared to healthy controls, the level of MACC1
transcripts was significantly upregulated at primary
diagnosis of ovarian cancer [estimated difference
(ED) = 0.22, CI = (0.03–0.49); P = 0.024; Fig. 1A + B].
ROC curve analysis revealed that the level of MACC1
at primary diagnosis discriminates ovarian cancer
1271Molecular Oncology 13 (2019) 1268–1279 ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
T. Link et al. Circulating MACC1 and S100A4 in ovarian cancer
patients from healthy controls with an area under the
curve (AUC) of 0.65 [CI = (0.53–0.77); Fig. S1]. The
level of S100A4 was likewise upregulated at primary
diagnosis [ED = 108, CI = (59–188); P < 0.001) and
discriminated cancer patients from healthy controls with
an AUC of 0.81 [CI = (0.70–0.91); Fig. 1C + D,
Fig. S1]. During surgery and adjuvant chemotherapy,
progression of MACC1 and S100A4 transcript levels
was highly comparable. One week after surgery, both
transcripts strongly increased [MACC1: ED = 0.75,
CI = (0.45–1.05); P < 0.001; S100A4: ED = 298,
CI = (204–411); P < 0.001] and then declined in the
course of adjuvant chemotherapy, gradually approach-
ing the level of healthy controls over time. Until begin-
ning of chemotherapy, both transcripts were still
significantly elevated compared to healthy controls
(Fig. 1A + C).
There was a strong correlation between circulating
MACC1 and S100A4 transcript levels at primary diag-
nosis and across all longitudinal follow-up samples
[correlation coefficients (r): 0.877, 0.876, 0,786, 0.703,
0.661, respectively; P < 0.001; Fig. 2]. Interestingly,
there was no correlation between the level of MACC1
and the clinically established serum marker CA125 at
Fig. 1. The dynamics of circulating MACC1 and S100A4 transcripts in the course of surgery and adjuvant chemotherapy. Level of circulating
MACC1 (A + B) and S100A4 (C + D) serum transcripts in ovarian cancer patients at (1) primary diagnosis (n = 77) and among four
longitudinal serum samples per patient, obtained (2) one week after primary surgery (n = 72), (3) before platinum-based chemotherapy
(n = 63), (4) after third cycle of chemotherapy (n = 53), and (5) after the completion of chemotherapy (n = 53), compared to healthy controls
(n = 25). The whiskers are drawn down to the 10th percentile and up to the 90th percentile. Values below or above the whiskers are
shown as individual dots. The median is plotted at the line in the middle of the box. For those patients with a complete set of all 5 blood
samples (n = 31), heat maps were drawn, visualizing the individual course of MACC1 (B) or S100A4 (D). P-values, according to the two-
sided Wilcoxon test for paired samples and according to the two-sided Mann–Whitney-U-Test for independent samples, are indicated.
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any of the investigated follow-up samples. The same
trend was true for S100A4; there was merely a weak
correlation between S100A4 and CA125 before
chemotherapy (r = 0.269; P = 0.047) and after comple-
tion of chemotherapy (r = 0.311; P = 0.029), but espe-
cially at primary diagnosis and during chemotherapy,
CA125 and S100A4 serum levels were independent
from each other.
Conclusively, circulating MACC1 and S100A4
transcripts are significantly elevated in serum of ovar-
ian cancer patients and show a high correlation in
the course of surgery and chemotherapy, which is
mostly independent from CA125 serum levels. Com-
pared to MACC1, S100A4 levels allow superior dis-
crimination between ovarian cancer patients and
healthy controls.
3.2. Association of circulating MACC1 and
S100A4 transcript levels with the patient’s
clinicopathological parameters
We related serum levels of circulating MACC1 and
S100A4 transcripts with the patient’s
clinicopathological data. Higher levels of MACC1 and
S100A4 transcripts at primary diagnosis correlated
with advanced disease, indicated by a higher FIGO
stage (P = 0.046, P = 0.008, respectively) and an
increased load of malignant ascites [MACC1:
ED = 0.37, CI = (0.11–0.73); P = 0.008; S100A4:
ED = 118, CI = (43–224); P = 0.002). Interestingly,
higher levels of both candidate transcripts at primary
diagnosis were associated with residual tumor burden
left after primary debulking [MACC1: ED = 0.34,
CI = (0.07–0.70); P = 0.011; S100A4: ED = 115,
CI = (24–203); P = 0.006; Fig. 3).
Collectively, high circulating MACC1 and S100A4
levels in serum of ovarian cancer patients correlate
with advanced disease and predict suboptimal primary
debulking surgery without achieving macroscopically
complete tumor resection.
3.3. Prognostic relevance of circulating MACC1
and S100A4 transcripts
In order to study the prognostic relevance of serum
MACC1 and S100A4 transcripts at primary diagnosis,
Fig. 2. Correlation between circulating MACC1 and S100A4 transcript levels. Coherence of MACC1 and S100A4 values for all blood
samples taken at primary diagnosis and at four defined reading points in the course of primary surgery and adjuvant chemotherapy (1: at
primary diagnosis; 2: one week after primary surgery; 3: before platinum-based chemotherapy; 4: after third cycle of chemotherapy; 5: after
the completion of chemotherapy). Correlation coefficients and P-values, according to Spearman’s rank-order test, are indicated.
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we performed univariate Cox regression analysis. A
MACC1 level increase of 1 relative unit was associated
with a 40% increase in the risk of recurrence [hazard
ratio (HR) = 1.40, confidence interval (CI) = (1.12–
1.74); P = 0.003] and with a 58% increase in the risk
of death [HR = 1.58, CI = (1.21–2.06); P < 0.001].
Upon doubling of the MACC1 level, we observed a
39% increase in the risk of recurrence [HR = 1.39,
CI = (1.09–1.77); P = 0.009] and a 53% increase in the
risk of death [HR = 1.53, CI = (1.10–2.13); P = 0.012;
Fig. S2].
An increase of 1 relative unit for S100A4 was associ-
ated with a 0.2% increase in the risk of recurrence
[HR = 1.002, CI = (1.0006–1.003); P = 0.001] and with
a 0.1% increase in the risk of death [HR = 1.001,
CI = (1.0005–1.002); P = 0.002]. Upon doubling of the
S100A4 level, we observed a 37% increase in the risk
of recurrence [HR = 1.37, CI = (1.08–1.74); P = 0.01]
and a 43% increase in the risk of death [HR = 1.43,
CI = (1.03–1.99), P = 0.035; Fig. S2].
Additionally, Kaplan–Meier analysis and the log-
rank test were performed. Patients with high levels of
circulating MACC1 transcripts had a significantly
decreased PFS [P = 0.03, HR = 1.98, CI = (1.06–3.72)]
and a decreased OS [P = 0.032, HR = 2.43,
CI = (1.05–5.64)] compared to patients with low
MACC1 levels (Fig. 4A). Accordingly, patients with
high levels of circulating S100A4 transcripts had a sig-
nificantly decreased PFS [P = 0.002, HR = 2.74
CI = (1.39–5.02)] and a significantly decreased OS
[P = 0.039, HR = 2.41, CI = (1.02–5.84)] compared to
patients with low S100A4 levels (Fig. 4B).
We additionally performed multivariate Cox regres-
sion analysis with PFS or OS as selected outcome vari-
ables, including MACC1 and S100A4 levels and
established risk factors of ovarian cancer, that is, age,
presence of malignant ascites, tumor stage, histology
and general state of health, according to the risk clas-
sification of the American Society of Anesthesiologists
(ASA). We could not confirm that MACC1 and
S100A4 transcript levels are independent predictors of
decreased PFS and OS (Fig. S3).
Subsequently, we analyzed prognostic relevance of
MACC1 and S100A4 levels in the longitudinal fol-
low-up samples. Considering the level of MACC1
and S100A4 independently at each reading point of
blood sampling (thus disregarding the individual
time-dependent course), their levels among all follow-
up samples did not provide prognostic information
(Fig. S2). In a more detailed analysis, we performed
univariate Cox regression analysis, now incorporating
MACC1 or S100A4 values as time-dependent vari-
ables across all reading points of blood drawing. The
time-dependent course of MACC1 and S100A4 tran-
scripts levels did not predict risk of recurrence or risk
of death.
Finally, assuming a linear change of MACC1 or
S100A4 values between the investigated follow-up
reading points, we plotted for each patient a dynamic
curve by interconnecting the values for MACC1 and
S100A4, thus reflecting the individual course of
MACC1 or S100A4 for each patient during surgery
and chemotherapy (Fig. 5A + B). From each curve,
the AUC was calculated and then applied for
Kaplan–Meier analysis. Therefore, all patients were
stratified into a high-AUC group (defined as an AUC
value above the median level) and into a low-AUC
group (defined as an AUC value below the median
level). There was no statistically significant difference
between MACC1 AUC high vs. low patients
(Fig. 5C) or between S100A4 high vs. low patients
(Fig. 5D).
We conclude that high levels of circulating MACC1
or S100A4 transcripts at primary diagnosis (but not
Fig. 3. Association of circulating MACC1 and S100A4 transcript levels with debulking efficiency. Circulating MACC1 (A) and S100A4 (B)
transcript levels at primary diagnosis in ovarian cancer patients with a macroscopic complete tumor resection vs. patients with any residual
tumor. The whiskers are drawn down to the 10th percentile and up to the 90th percentile. Values below or above the whiskers are shown
as individual dots. The median is plotted at the line in the middle of the box. P-values, according to two-sided Mann–Whitney-U-Test, are
indicated.
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among follow-up samples during surgery and adjuvant
chemotherapy) are unfavorable prognostic factors for
ovarian cancer patients and indicate poor prognosis.
4. Discussion
In the present liquid biopsy approach, we systemati-
cally analyzed clinical relevance of circulating MACC1
and S100A4 transcripts in ovarian cancer patients. We
report that high serum levels of both transcripts at pri-
mary diagnosis (but not in the course of chemotherapy)
are associated with advanced disease, predict subopti-
mal primary debulking, and indicate poor survival.
The mechanisms, how nucleic acids are released into
the bloodstream, are still unclear. However, robust
data suggest that fragmented tumor DNA or RNA
found in plasma is derived mostly from apoptotic can-
cer cells or by active secretion mechanism involving
microvesicles, such as exosomes (Schwarzenbach, 2015;
Schwarzenbach et al., 2011). We observed that serum
levels of both, MACC1 and S100A4, are significantly
upregulated at primary diagnosis of ovarian cancer,
compared to healthy controls. This is in accordance
with our previous studies on CRC, in which MACC1
was shown to be significantly upregulated either in
malignant CRC tissue vs. healthy colonic mucosa or in
plasma from CRC patients vs. plasma from healthy
controls (Ashktorab et al., 2016; Stein et al., 2009a).
The same holds true when comparing MACC1 levels
in plasma from gastric cancer patients compared to
healthy controls (Ashktorab et al., 2016; Burock et al.,
2015; Stein et al., 2012). Moreover, we have also
observed upregulation of S100A4 transcripts in plasma
from patients with CRC or gastric cancer (Stein et al.,
2011, 2012). Our data now extend our knowledge on
MACC1 and S100A4 to ovarian cancer.
In contrast to MACC1, S100A4 levels in serum of
ovarian cancer patients showed only a small overlap
to healthy controls, resulting in a good discrimination
between ‘ovarian cancer’ and ‘healthy’ (AUC = 0.81).
Future studies will have to address, whether the circu-
lating S100A4 transcript level could be used as a
blood-based screening marker for ovarian cancer.
Therefore, independent patient cohorts with low-stage
ovarian cancer (FIGO I-II) will be necessary.
The levels of circulating MACC1 or S100A4 tran-
scripts showed a characteristic and highly concordant
dynamic in the course of primary surgery and
chemotherapy. Both transcript levels strongly increased
at the measure point one week after primary debulking
surgery. However, this increase did neither correlate
with debulking efficiency nor with residual tumor bur-
den or prognosis, suggesting that this phenomenon
could be caused by an unspecific and transient release
of MACC1 and S100A4 mRNA into the blood, possi-
bly due to tissue damage during surgery.
Applying different PCR-based methods for MACC1
and S100A4 detection, we report that circulating
Fig. 4. Prognostic relevance of circulating MACC1 and S100A4 transcripts at primary diagnosis. Kaplan–Meier analysis comparing
progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with high levels of circulating MACC1 (A) or S100A4 (B)
transcripts vs. low levels of circulating MACC1 or S100A4 transcripts. High MACC1 levels were defined as a MACC1 value > 0.776%
calibrator (for PFS analysis) and as > 0.946% calibrator (for OS analysis). High S100A4 levels were defined as a S100A4 value above the
median (for PFS and OS analysis). P-values, according to log-rank test and hazard ratio (HR), are indicated.
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MACC1 and S100A4 transcript levels strongly corre-
late at all investigated reading points. Although
MACC1 and S100A4 are involved in different biologi-
cal pathways, that is, MACC1 as a key regulator of
HGF-MET signaling (Stein et al., 2009a) and S100A4
as a transcriptional target of b-catenin/T-cell factor
signaling (Stein et al., 2006), our data suggest that
MACC1 and S100A4 might be co-regulated in cancer.
Further, since MACC1 is reported to regulate Wnt/b-
catenin signaling (Zhen et al., 2014), also a direct regu-
lation of S100A4 as a Wnt/b-catenin signaling target
cannot be excluded. Therefore, the highly concordant
dynamics of MACC1 and S100A4 transcripts in serum
of ovarian cancer patients could be explained by a
proportional release upon apoptosis or by a possibly
co-regulated active secretion.
Since we found that levels of MACC1 and S100A4
transcripts at primary diagnosis correlated with FIGO
stage, we suggest that a significant proportion of
MACC1 and S100A4 transcripts is derived from
ovarian cancer cells and reflects the patient’s individual
tumor load. This is further supported by our finding
that high serum levels were associated with suboptimal
debulking surgery. We hypothesize that high serum
levels of these transcripts are associated with advanced
tumors with aggressive and complex growth patterns,
which are more difficult to be resected.
The strength of our study is that we analyzed serum
MACC1 and S100A4 transcripts not only at primary
diagnosis but also in an extended serum set of four
longitudinal follow-up samples per patient in the
course of surgery and chemotherapy. Taking advan-
tage of these extended serum sets, we can now draw
the substantiated conclusion that high MACC1 and
S100A4 serum levels at primary diagnosis have prog-
nostic relevance and indicate poor survival. Since
serum levels of MACC1 and S100A4 were independent
from CA125 levels, they could be useful as auxiliary
liquid biopsy markers for stratifying prognosis. Such
an unfavorable prognostic impact of high MACC1
Fig. 5. Prognostic relevance of circulating MACC1 and S100A4 transcripts in the course of adjuvant chemotherapy. Assuming a linear change
of MACC1 or S100A4 values, ‘dynamic curves’ were plotted for each patient, reflecting the individual course of MACC1 or S100A4 for all
patients with a complete set of blood samples (n = 31) in the course of surgery and adjuvant chemotherapy. From each plot, the area under the
curve (AUC) was calculated for an observation time of 146 days (which was an available time period for all included patients) and was applied
for Kaplan–Meier analysis. The Figure shows two representative ‘dynamic curves’ for circulating MACC1 transcripts with a low AUC (defined as
an AUC value below the median level, (A) vs. high AUC (defined as an AUC value equal or above the median level, (B). Kaplan–Meier curves
were drawn, comparing (C) progression-free survival (PFS) and (D) overall survival (OS) of ovarian cancer patients with high AUC of MACC1 or
S100A4, respectively, vs. patients with low AUC of MACC1 or S100A4, respectively. P-values, according to log-rank test, are indicated.
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and S100A4 expression at primary diagnosis has
already been reported by our group and by indepen-
dent investigators for a variety of other solid cancer
entities, including CRC, gastric cancer, pancreatic can-
cer or glioblastoma (Burock et al., 2015; Hagemann
et al., 2013; Huang et al., 2016; Kikuchi et al., 2006;
Stein et al., 2009a); this either among primary-tumor
or blood-based approaches. Nevertheless, despite a
very recent preliminary study, investigating clinical rel-
evance of S100A4 protein in serum (Lv et al., 2018),
this is the first study on MACC1 and S100A4 serum
transcripts in ovarian cancer. As a limitation of our
study, a complete series of longitudinal follow-up sam-
ples was only available from a part of our patients
(n = 31) and not from the entire cohort.
We encourage further investigation, considering
MACC1 and S100A4 as a potential therapeutic target
for ovarian cancer. In this context, we have already
designed pharmacological strategies for inhibiting
MACC1 by the small-molecule transcriptional inhibi-
tors lovastatin or rottlerin for CRC (Juneja et al.,
2017). Moreover, we showed that the antihelminthic
drug niclosamide inhibits S100A4 transcription and we
are currently performing a clinical phase II trial on
stage IV CRC, in which niclosamide is applied in
terms of a drug repositioning approach (EudraCT
2014-005151-20, NCT02519582). Future studies will
have to address whether this concept could be trans-
ferred to ovarian cancer.
5. Conclusions
We report that high MACC1 and S100A4 transcript
levels at primary diagnosis of ovarian cancer are asso-
ciated with advanced disease and predict poor progno-
sis. Our data harmonize with the previously shown
oncogenic and metastasis-initiating impact of MACC1
and S100A4 and extend our knowledge of these genes
to innovative liquid biopsy approaches for ovarian
cancer. Furthermore, we encourage future translational
investigations with MACC1 and S100A4 as therapeu-
tic targets for ovarian cancer.
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Fig. S1. Discrimination of circulating MACC1 and
S100A4 transcripts between ovarian cancer patients
and healthy controls. ROC curve analysis was per-
formed to assess, whether circulating MACC1 or
S100A4 serum levels at primary diagnosis enable dis-
crimination between ovarian cancer patients and
healthy controls. The corresponding area under the
curve (AUC) values are indicated.
Fig. S2. Prognostic relevance of circulating MACC1
and S100A4 transcripts at primary diagnosis and in
the course of treatment. An univariate Cox regression
analysis was performed. The figure shows the natural
logarithm of the hazard ratios (upon doubling of the
MACC1 or S100A4 levels) and the corresponding con-
fidence intervals.
Fig. S3. Prognostic relevance of circulating MACC1
and S100A4 transcripts at primary diagnosis in rela-
tion to established risk factors of ovarian cancer. A
multivariate Cox regression analysis was performed,
adjusted for established ovarian cancer risk factors.
The figure shows the natural logarithm of the hazard
ratios and the corresponding confidence intervals.
1279Molecular Oncology 13 (2019) 1268–1279 ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
T. Link et al. Circulating MACC1 and S100A4 in ovarian cancer
